<DOC>
	<DOCNO>NCT02157311</DOCNO>
	<brief_summary>Evaluate 48 week , capacity weekly strategy 4 consecutive day treatment follow 3 day treatment , HIV-1 treat patient undetectable viral load least 12 month continuous antiretroviral regimen unchanged least 4 month , maintain therapeutic success define absence virological failure ( 2 consecutive viral load &gt; 50 cp/mL ) absence interruption therapeutic strategy ( interruption change `` 4 day / 3 day `` strategy time longer 30 consecutive day ) .</brief_summary>
	<brief_title>4 Consecutive Days Treatment Followed 3 Days Off Treatment , HIV Patients</brief_title>
	<detailed_description>Methods : Open-label , multicentric , prospective , non-randomized , non-controlled trial evaluate 48 week , capacity weekly strategy 4 consecutive day treatment follow 3 day treatment , HIV-1 treat patient undetectable viral load least 12 month continuous antiretroviral regimen unchanged least 4 month , maintain therapeutic success define absence virological failure ( 2 consecutive viral load &gt; 50 cp/mL ) absence interruption therapeutic strategy ( interruption change `` 4 day / 3 day `` strategy time longer 30 consecutive day ) . Allocation : Non-randomized Endpoint Classification : Safety/Efficacy Study Primary Purpose : Treatment Enrollment : 100 patient</detailed_description>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>• HIV1 document infection Age 18 year old HIV1 viral load always ≤ 50 cp/mL least 12 month ( minimum 3 measure last 12 month , include screen ) CD4+ lymphocytes count &gt; 250/mm3 , least 6 month Treatment stable regimen least 4 month prior screen , contain 2 nucleoside/nucleotide analog reverse transcriptase inhibitor ( NRTI ) combine , either 1 nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , 1 ritonavirboosted protease inhibitor ( PI/r ) . The list accept antiretroviral drug limit : 1 . NRTI : tenofovir , emtricitabine , abacavir , lamivudine 2 . PI/r : lopinavir/r , darunavir/r atazanavir/r 3 . NNRTI : efavirenz , rilpivirine etravirine . Exclusive antiretroviral 3 drugtherapy ( 4 drugtherapy ) A least one genotypic resistance test available ( reverse transcriptase and/or protease amino acid sequence , accord ongoing antiretroviral drug ) ; genotypic resistance test ( ) available medical history , susceptibility every ongoing antiretroviral drug must demonstrate Clearance creatinine &gt; 60 mL/min ( MDRD ) ASAT ALAT &lt; 3 ULN Hemoglobin &gt; 10 g/dl Platelets count &gt; 100 000/mm3 Negative pregnancy test potential childbearing woman mechanical contraception sexual intercourses Patient live France affiliate social security system Written inform consent • HIV2 infection HBV infection ( positive HBs antigen ) isolate positive HBc antibody HCV infection require specific treatment 51 week trial At least one know resistance one ongoing antiretroviral drug Exclusive antiretroviral 3 drugtherapy ( 4 drugtherapy ) No genotypic resistance test available Ongoing either interferon , interleukin treatment , every immuno / chemotherapy Progressive opportunistic infection , ongoing treatment opportunistic infection tuberculosis Patient irregular followup treatment adherence problem Any condition ( alcohol , drug abuse… ) compromise treatment adherence , treatment safety , and/or study adherence Progressive neurological disorder ( meningitis , encephalitis , myelitis… ) relate HIV infection Medical history severe neuropsychiatric disorder , insufficient treatment efficacy Subject legal guardianship incapacitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>simplification ,</keyword>
	<keyword>treatment discontinuation</keyword>
	<keyword>virological success</keyword>
	<keyword>four day week</keyword>
</DOC>